US › Healthcare

Emergent Biosolutions Inc (EBS)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$7.57+2.16%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$156.1M
Revenue YoY
-29.7%
Net profit
$6.8M
Profit YoY
-90.0%
EPS
$0.21
EPS estimate
$-0.25
Net margin
4.4%

EPS came in at 0.21 against a street estimate of -0.25 — a beat of 184.0%.

Key statistics

Market cap
$377.2M
Forward P/E
2.1
P/B
0.71
Book value
$10.10
EPS (TTM)
$-0.19
52-week high
$14.06
52-week low
$6.03
50-day MA
$8.07
200-day MA
$9.61
Beta
2.34

Analyst view

Analysts rate Emergent Biosolutions Inc a buy (2 buy, 0 hold, 1 sell out of 3) with an average price target of $12.00.

Shareholding

Insiders
3.85%
Institutions
87.61%

Largest institutional holders

FundStake
BlackRock Inc8.41%
State Street Corp5.52%
Dimensional Fund Advisors, Inc.5.34%
American Century Companies Inc4.70%
Vanguard Capital Management, LLC4.38%
Charles Schwab Investment Management Inc2.92%
Acadian Asset Management LLC2.68%
Geode Capital Management, LLC2.47%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Emergent Biosolutions Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.